Order Article Reprints

Imran M, Khan SA, Alshammari MK, Alreshidi MA, Alreshidi AA, Alghonaim RS, Alanazi FA, Alshehri S, Ghoneim MM, Shakeel F. Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines. 2021; 9(12):1938. https://doi.org/10.3390/biomedicines9121938

Imran, Mohd, Shah Alam Khan, Mohammed Kanan Alshammari, Meshal Ayedh Alreshidi, Abeer Abdullah Alreshidi, Rawan Sulaiman Alghonaim, Fayez Aboud Alanazi, Sultan Alshehri, Mohammed M. Ghoneim, and Faiyaz Shakeel. 2021. "Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions" Biomedicines 9, no. 12: 1938. https://doi.org/10.3390/biomedicines9121938

Imran, M., Khan, S. A., Alshammari, M. K., Alreshidi, M. A., Alreshidi, A. A., Alghonaim, R. S., Alanazi, F. A., Alshehri, S., Ghoneim, M. M., & Shakeel, F. (2021). Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions. Biomedicines, 9(12), 1938. https://doi.org/10.3390/biomedicines9121938